Cann Group reports revenue spike as recruitment for sleep disturbance trial gets underway by Martin Lane April 28, 2022April 28, 2022 Cann Group has reported unaudited sales revenue for the quarter ending March 31 2022 of A$1.27 […]
CBD ‘tolerated’ in UK but no products have yet been authorised, Food Standards Agency stresses by Steve Jones April 14, 2022April 14, 2022
Cann Group inks Satipharm deal with GSK Consumer Healthcare by Martin Lane April 6, 2022April 6, 2022
Satipharm among CBD products given green light by UK Food Standards Agency by Martin Lane April 1, 2022April 7, 2022
Over-the-counter race hots up as Cann Group prepares to recruit patients for sleep disturbance trial by Steve Jones February 16, 2022February 16, 2022
Medlab signs deal to promote Cann Group’s Satipharm product to doctors by Steve Jones February 1, 2022February 1, 2022
Cann Group and Emyria go their separate ways on S3 registration by Martin Lane August 13, 2021August 13, 2021
A year of frustration but Cann Group vows to deliver for shareholders and consumers by Steve Jones August 12, 2021August 17, 2021
